title: Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future".
authors.affiliation: ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru ana.requena@cresib.cat.
authors.forename: Ana
authors.initials: A
authors.lastname: Requena-Méndez
authors.affiliation: Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
authors.forename: Geraint
authors.initials: G
authors.lastname: Davies
authors.affiliation: Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru TB Centre and Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
authors.forename: David A J
authors.initials: DA
authors.lastname: Moore
mesh_terms: D000995:Antitubercular Agents / Q000493:pharmacokinetics*; D004041:Dietary Fats / Q000493:pharmacokinetics*; D005260:Female; D018565:Food-Drug Interactions; D006801:Humans; D007538:Isoniazid / Q000493:pharmacokinetics*; D008297:Male; D012293:Rifampin / Q000493:pharmacokinetics*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D004041:Dietary Fats; D007538:Isoniazid; D012293:Rifampin